2025 A-share performance quick reports released in quick succession: 70% revenue growth, leading companies in niche sectors perform outstandingly

Recently, listed companies have been densely releasing their 2025 earnings forecasts.

iFinD data shows that as of February 28, 2025, 1,011 A-share companies have publicly announced their performance forecasts for 2025. Seventy percent of these companies achieved year-over-year revenue growth, and nearly 60% reported positive growth in net profit attributable to shareholders. A number of companies in high-end manufacturing, semiconductor materials, and innovative pharmaceuticals sectors performed especially well.

Notably, some leading companies in niche segments have doubled their revenue and net profit through technological breakthroughs and increased demand, attracting significant market attention. Additionally, some companies not only posted impressive performance but also saw their stock prices surge, achieving a double boost in both performance and valuation.

Nearly 70% of companies reported revenue growth

From the disclosed performance forecasts, it appears that A-share listed companies experienced a general recovery in revenue last year. According to iFinD data, 699 companies reported year-over-year revenue increases, accounting for 69.14%, reflecting an overall positive business trend. Among them, 90 companies saw revenue growth of over 50%, achieving leapfrog growth.

On the growth leaderboard, Haichuang Pharmaceutical, Zhixiang Jintai, and Cambrian rank the top three in revenue growth, with 2025 revenues of 0.21 billion yuan, 2.31 billion yuan, and 64.97 billion yuan, respectively, representing year-over-year increases of 5536.26%, 666.65%, and 453.21%.

Specifically, Haichuang Pharmaceutical (688302.SH) is a global innovative drug company focused on cancer and metabolic diseases. Its revenue growth mainly stems from the approval and sales of its first Class 1 new drug, Dronzaruzumab soft capsules, in May 2025, which generated drug sales income. Zhixiang Jintai (688443.SH) concentrates on autoimmune, infectious, and tumor treatment areas. The company expanded sales of its first commercialized product, Selicizumab (Jinlixi®) injection, driving year-over-year sales growth. Both companies belong to the biopharmaceutical industry.

Cambrian (688256.SH), a leader in domestic AI chips, focuses on R&D and technological innovation in AI chip products. In its performance forecast, Cambrian stated that in 2025, benefiting from the rising demand for computing power in AI industry, the company continued to expand its market with its competitive products and actively promoted AI application scenarios, resulting in significant revenue growth compared to the previous year. The substantial increase in revenue helped the company turn losses into profits.

Following the top tier, companies like Zhongwu Drone (688297.SH), Mengsheng Electronics (688311.SH), Sansheng Guojian (688336.SH), and Moore Threads (688795.SH) also maintained rapid growth, with revenues of 3.016 billion yuan, 4.199 billion yuan, 1.506 billion yuan, and 2.4337 billion yuan in 2025, representing year-over-year increases of 340.11%, 276.78%, 251.81%, and 243.37%, covering sectors like low-altitude economy, innovative pharmaceuticals, and AI chips.

In terms of revenue scale, leading companies have a clear advantage. Among those with disclosed forecasts, nine companies have revenues exceeding 100 billion yuan. Among them, China Merchants Bank (600036.SH), Poly Developments (600048.SH), and Jinyu (300999.SZ) rank the top three, with 2025 revenues of 3.3752 trillion yuan, 3.0826 trillion yuan, and 2.4513 trillion yuan, demonstrating strong operational resilience.

Profitability also improves simultaneously

Alongside steady revenue growth, the profitability of listed companies has also significantly increased. According to iFinD data, among the companies with disclosed forecasts, 578 reported year-over-year growth in net profit attributable to shareholders, accounting for 57.17%. Of these, 193 companies saw net profit increases of over 50%, with companies like Sinocare (688108.SH) achieving multiple-fold growth.

On the profit growth leaderboard, Yuanjie Technology (688498.SH), Sinocare, and Huafeng Technology (688629.SH) rank the top three. Sinocare’s net profit attributable to shareholders in 2025 reached 47.2863 million yuan, a substantial increase from 1.4978 million yuan the previous year. Sinocare specializes in high-end interventional medical devices, with products sold globally.

Yuanjie Technology is involved in semiconductor crystal growth, wafer processing, chip testing, and packaging. Its improved performance is mainly due to growth in data center business, which has higher gross margins than telecom markets. Huafeng Technology, a global provider of optoelectronic connectors and interconnection solutions, reported breakthroughs in server high-speed cable modules and other products, driving performance improvement.

In terms of net profit scale, 14 companies with disclosed forecasts have net profits exceeding 10 billion yuan, including China Merchants Bank, Industrial Bank (601166.SH), CITIC Bank (601998.SH), Pudong Development Bank (600000.SH), and China Yangtze Power (600900.SH).

Additionally, among companies with disclosed forecasts, 436 achieved both revenue and profit growth, including industry leaders like Byte Storage (688525.SH), Ledi Harmonic (688017.SH), Zhongji Xuchuang (300308.SZ), and CITIC Securities (600030.SH), among others.

Some companies’ stock prices also strengthened in tandem

Against the backdrop of continuous performance improvement, capital has begun to focus on companies with strong performance certainty and upward industry trends, leading to a “performance growth + stock price rise” double boost for some listed firms.

Examples include Ouke Yi (688308.SH), Yinneng Power (920046.BJ), and Jepte (688025.SH). Ouke Yi achieved revenue of 1.457 billion yuan in 2025, up 29.30%; net profit attributable to shareholders was 104 million yuan, up 81.18%. The company’s revenue and net profit both maintained steady growth. Ouke Yi is engaged in the R&D, production, and sales of cemented carbide products and CNC tools. In its performance forecast, the company stated that as a leading enterprise in cemented carbide cutting tools, it benefits from capital and scale advantages, achieving simultaneous growth in product volume and price. Its stock price increased by over 134% within the year. Additionally, Yinneng Power and Jepte saw increases of 122.68% and 100.15%, respectively.

Furthermore, Guanggang Gas achieved revenue of 2.424 billion yuan in 2025, up 15.26%; net profit attributable to shareholders was 286 million yuan, up 15.39%. The company focuses on electronic bulk gases and has built a fully controllable industrial gas supply chain, benefiting deeply from the localization wave in semiconductor and display industries. Thanks to stable performance, Guanggang Gas has recently attracted capital, with its stock price rising by 76.75% within the year.

Analysts suggest that for investors, during the performance disclosure window, selecting high-quality companies and avoiding performance traps requires combining performance data with company operation logic. When screening for quality companies, besides focusing on sustainable growth, investors should also consider industry prosperity, valuation matching, and financial health indicators.